418P Two-year Follow-Up Data on the Efficacy and Safety of KN026, a HER2-targeted Bispecific Antibody Combined with Docetaxel As First-Line Treatment for HER2-positive Recurrent/metastatic Breast Cancer
Annals of Oncology(2023)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要